

Press Release

September 20, 2016

MagForce congratulates team of Prof. Stummer of University Hospital Münster on winning Best Abstract Award at EANS 2016 in Athens, Greece

Berlin, Germany and Nevada, USA, September 20, 2016 - MagForce AG (Frankfurt, Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, congratulates Prof Dr Walter Stummer, Director of the Department of Neurosurgery, and the lead investigator of the Post-Marketing study at the University Hospital Münster and his team on winning the prestigious “EANS2016 Best Abstract Award”. The 2016 EANS Congress was held by the European Association of Neurosurgical Societies from September 4-8, 2016 in Athens, Greece.

The award for the winning abstract titled *“NanoPaste’: Thermo-therapy via nanoparticles directly instilled onto glioma resection cavity walls - technique and feasibility¹”* was handed to Dr Mohammed Jaber, who also held the oral presentation in Athens, during the EANS 2016 Closing Ceremony on Thursday, September 8, 2016.

“The abstract introduces a new nanoparticles application technique called ‘NanoPaste’ that was developed for use during thermo-therapy in the treatment of glioblastoma and used first in man at our department. The results of our new technique show that we were able to create sufficient nanoparticle concentrations to reach effective thermo-therapy in the glioma resection cavity wall and its vicinity. In comparison to stereotactic techniques with all their imponderabilities in scarred and pretreated tissues, application was technically easy, controllable, and quick to perform,” said Dr. Johannes Woelfer, deputy director of the neurosurgical department, Clinic and Policlinic for Neurosurgery, University Hospital Münster, and co-presenter at the 2016 EANS Congress.

The authors state that the prognosis for glioma patients is still dim especially because most glioma recurrences are observed in the direct vicinity of the original resection cavity after the tumor has been removed. For more local control of remaining tumour infiltration, they conclude, that the promising concept of thermo-therapy for tumor ablation and as a radiosensitizer in glioma therapy could be boosted by better applicability of heat-focussing nanoparticles around the resection rim as demonstrated by their “NanoPaste” method. The concept in itself awaits evaluation of survival times and of the cumulative toxic potential of this multimodal regimen, as is currently underway.

“MagForce congratulates the team of Prof. Stummer and Dr. Woelfer of the University Hospital Münster on this winning abstract,” said Ben Lipps, CEO of MagForce AG. “With keen interest, we

¹M.Jaber¹, M.Yavuz¹, S. Maring², W. Stummer¹, J.Wölfer;

¹Universitätsklinikum Münster, Neurosurgery, Münster, Germany, ²Universitätsklinikum Münster, 2 Radiation Oncology, Münster, Germany

Press Release

MagForce AG • Max-Planck-Straße 3 • 12489 Berlin • Germany • www.magforce.com

For further information:
Barbara von Frankenberg
VP Communications
& Investor Relations

bfrankenberg@magforce.com
T +49-30-308380-77
F +49-30-308380-99
M +49 173-2792768

follow the developments of the neurosurgeons and radiologists working with NanoTherm™ and their experiences. We are excited that the "NanoPaste" method, utilizing our proprietary NanoTherm® particles, could be an effective technique for improving treatment outcome for patients."

About EANS 2016

The European Association of Neurosurgical Societies (EANS) is a fast-developing independent association, both of European neurosurgical societies and of individual neurosurgeons from all over the world which arranges congresses, scientific meetings and symposia, including the biennial European Congress of Neurosurgery, the Annual EANS Meetings and European Training courses.

This year's congress topic of EANS was "Neurosurgery: from the Classics to the future." Exploring the past, present and future of the neurosurgical specialty, the European Congress took an in-depth look at current standards, advances in this field, and gave an outlook for the profession and developments in neurosurgery. The Scientific Programme covered the whole neurosurgical spectrum. Invited speakers, most eminent neurosurgeons from both within Europe and throughout the world, considered the benefits of tried and tested 'classical' neurosurgical techniques, and compared them with their cutting-edge alternatives, often minimally invasive techniques.

Role of NanoTherm™ Therapy in the Treatment of Brain Tumors

NanoTherm™ therapy is an intratumoral thermotherapy which aims to help patients with brain tumors. It can be used as a monotherapy or in combination with radiotherapy and/or chemotherapy to enhance their effectiveness.

With NanoTherm™ Therapy, the magnetic fluid injected into a tumor is heated through a very fast alternating magnetic field. Through the heat, tumor cells are either destroyed or sensitized for additional therapies such as radiotherapy and/or chemotherapy; thus, the efficacy of the additional therapies is improved.

MagForce AG has CE mark (European Certification) in Germany and in the EU 28 to treat brain tumors with NanoTherm™ Therapy.

About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the entry standard of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm™ therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. Mithril Capital Management, a growth-stage technology fund founded by Ajay Royan and Peter Thiel, along with MagForce AG, are investors and

Press Release

MagForce AG • Max-Planck-Straße 3 • 12489 Berlin • Germany • www.magforce.com

For further information:
Barbara von Frankenberg
VP Communications
& Investor Relations

bfrankenberg@magforce.com
T +49-30-308380-77
F +49-30-308380-99
M +49 173-2792768

strategic partners in MagForce USA, Inc.

NanoTherm™, NanoPlan®, and NanoActivator® are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm™, NanoPlan, and NanoActivator® are trademarks of MagForce AG in selected countries.

For more information, please visit: www.magforce.com

Get to know our Technology: [video \(You Tube\)](#)

Stay informed and subscribe to our [mailing list](#)

For any further questions, please contact us at:

Patient Advocacy

Dr. Katarzyna Zarychta

+49 30 95 477 95-66

kzarychta@magforce.com

Medical Liaison

Dr. Ulrike Boettcher

+49 89 95 477 95-64

uboettcher@magforce.com

Media & Investors

Barbara v. Frankenberg

+49 30 30 83 80-77

bfrankenberg@magforce.com

Disclaimer

This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.

Press Release

MagForce AG • Max-Planck-Straße 3 • 12489 Berlin • Germany • www.magforce.com

For further information:
Barbara von Frankenberg
VP Communications
& Investor Relations

bfrankenberg@magforce.com
T +49-30-308380-77
F +49-30-308380-99
M +49 173-2792768